文献速递淋巴瘤造血干细胞移植与细胞治疗

外周T细胞淋巴瘤患者一线治疗后达完全缓解接受 upfront 自体干细胞移植:一项多中心真实世界分析

Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis.
PubMed 文献 · Br J Haematol · 2024-01-25

这项回顾性多中心研究纳入347例外周T细胞淋巴瘤一线治疗后达完全缓解的患者,其中257例接受巩固化疗(非ASCT组)、90例接受自体干细胞移植(ASCT组)。倾向评分匹配后两组2年治疗相关死亡率与复发率相近,但T细胞淋巴瘤亚组中ASCT组2年无进展生存率和总生存率优于非ASCT组,NK/T细胞淋巴瘤患者未见显著差异。

要点

  • 347例一线治疗后达完全缓解的PTCL患者中,90例接受ASCT、257例接受巩固化疗。
  • 倾向评分匹配后T细胞淋巴瘤亚组ASCT组2年PFS 73.4% vs 非ASCT组50.8%(p=0.024)。
  • NK/T细胞淋巴瘤患者中ASCT与非ASCT组未见显著差异。

核心结论

  • 真实世界数据显示,upfront ASCT是PTCL缓解期患者安全有效的巩固选择,尤其是T细胞淋巴瘤患者。

研究设计与样本

  • 回顾性、多中心研究,纳入347例一线治疗后达完全缓解的PTCL患者。
  • 257例接受巩固化疗(非ASCT组),90例接受ASCT(ASCT组)。

主要发现

  • 倾向评分匹配后,2年治疗相关死亡率ASCT组1.9% vs 非ASCT组2.0%(p=0.985)。
  • 倾向评分匹配后,2年复发率ASCT组24.7% vs 非ASCT组47.1%(p=0.021)。
  • T细胞淋巴瘤亚组2年无进展生存率ASCT组73.4% vs 非ASCT组50.8%(p=0.024)。
  • T细胞淋巴瘤亚组2年总生存率ASCT组92.1% vs 非ASCT组73.5%(p=0.021)。
  • NK/T细胞淋巴瘤患者中ASCT与非ASCT组未见显著差异。

临床怎么用

  • 作者认为,upfront ASCT是PTCL缓解期患者安全有效的巩固选择,尤其是T细胞淋巴瘤患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a retrospective, multicentre study to compare consolidation therapy with or without first-line autologous stem cell transplant (ASCT) for peripheral T-cell lymphoma (PTCL) patients in a real-world setting. We enrolled 347 PTCL patients who achieved complete response after first-line treatment. Of these, 257 received consolidation chemotherapy (non-ASCT group) and 90 received ASCT (ASCT group). Clinical outcomes were comparable between ASCT and non-ASCT groups. After propensity score matching, the 2-year cumulative incidence of treatment-related mortality and relapse remained similar between groups (1.9% vs. 2.0%, p = 0.985; 24.7% vs. 47.1%, p = 0.021). However, significant differences emerged in progression-free survival and overall survival probabilities. Within the T-cell lymphoma subgroup, ASCT patients exhibited favourable outcomes compared to non-ASCT patients: 2-year progression-free survival (73.4% vs. 50.8%, p = 0.024) and overall survival (92.1% vs. 73.5%, p = 0.021). Notably, no significant differences were observed for patients with NK/T-cell lymphoma. These real-world data suggest that up-front ASCT is a safe and effective consolidation option for PTCL patients in remission, particularly those with T-cell lymphoma.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yang P, Cai M, Cao Y, et al. Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis. Br J Haematol. 2024. PMID: 38272453. doi:10.1111/bjh.19317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。